These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 30847728

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R, May JR, Suri G, Young K, Brixner D, Oderda G, Biskupiak J, Tang D, Bhattacharyya S, Mishra D, Bhattacharyya D, Dalal AA.
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V, Zhong L, Narsipur N, Hays E, Tran DK, Rosario K, Wilson L.
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [Abstract] [Full Text] [Related]

  • 4. Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.
    Wan X, Zhang Y, Ma J, Tan C, Zeng X, Peng L.
    Breast; 2019 Feb; 43():1-6. PubMed ID: 30342258
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
    Janni W, Alba E, Bachelot T, Diab S, Gil-Gil M, Beck TJ, Ryvo L, Lopez R, Tsai M, Esteva FJ, Auñón PZ, Kral Z, Ward P, Richards P, Pluard TJ, Sutradhar S, Miller M, Campone M.
    Breast Cancer Res Treat; 2018 Jun; 169(3):469-479. PubMed ID: 29404806
    [Abstract] [Full Text] [Related]

  • 7. First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis.
    Huang X, Lin S, Rao X, Zeng D, Wang H, Weng X, Huang P.
    Clin Breast Cancer; 2021 Aug; 21(4):e479-e488. PubMed ID: 33676870
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.
    Biskupiak J, Oderda G, Brixner D, Tang D, Zacker C, Dalal AA.
    J Manag Care Spec Pharm; 2019 Aug; 25(8):859-866. PubMed ID: 31347980
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
    Masurkar PP, Damgacioglu H, Deshmukh AA, Trivedi MV.
    Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
    [Abstract] [Full Text] [Related]

  • 13. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC, de Groot S, Riemsma R, Fayter D, Armstrong N, Portegijs P, Duffy S, Kleijnen J, Al MJ.
    Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
    [Abstract] [Full Text] [Related]

  • 14. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Mistry R, Suri G, Young K, Hettle R, May JR, Brixner D, Oderda G, Biskupiak J, Tang D, Bhattacharyya D, Bhattacharyya S, Mishra D, Dalal AA.
    Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
    Gupta N, Gupta D, Dixit J, Mehra N, Singh A, Krishnamurthy MN, Jyani G, Rajsekhar K, Kalaiyarasi JP, Roy PS, Malik PS, Mathew A, Malhotra P, Gupta S, Kumar L, Kataki A, Prinja S.
    Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
    Cameron D, Kumar Sharma V, Biswas C, Clarke C, Chandiwana D, Pathak P.
    J Med Econ; 2023 Jul; 26(1):357-365. PubMed ID: 36797664
    [Abstract] [Full Text] [Related]

  • 18. Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand.
    Dajsakdipon T, Susiriwatananont T, Wongkraisri C, Ithimakin S, Parinyanitikul N, Supavavej A, Dechaphunkul A, Sunpaweravong P, Neesanun S, Akewanlop C, Dejthevaporn T, TSCO Breast Oncology Group.
    BMC Cancer; 2024 Aug 16; 24(1):1018. PubMed ID: 39152401
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer.
    Mamiya H, Tahara RK, Tolaney SM, Choudhry NK, Najafzadeh M.
    Ann Oncol; 2017 Aug 01; 28(8):1825-1831. PubMed ID: 28472324
    [Abstract] [Full Text] [Related]

  • 20. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
    Raphael J, Helou J, Pritchard KI, Naimark DM.
    Eur J Cancer; 2017 Nov 01; 85():146-154. PubMed ID: 28930692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.